A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood
Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas. We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine g...
Gespeichert in:
| Veröffentlicht in: | Neuro-oncology (Charlottesville, Va.) Va.), 2013-06, Vol.15 (6), p.783-787 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 787 |
|---|---|
| container_issue | 6 |
| container_start_page | 783 |
| container_title | Neuro-oncology (Charlottesville, Va.) |
| container_volume | 15 |
| creator | Cohen, Kenneth J Gibbs, Iris C Fisher, Paul G Hayashi, Robert J Macy, Margaret E Gore, Lia |
| description | Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas.
We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable.
ATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation.
The recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered. |
| doi_str_mv | 10.1093/neuonc/not021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3661102</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1551613596</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-f0f6080edff555adccf59a1eca32220d25c12ba5321f4c09f3c9a66b5d60d7de3</originalsourceid><addsrcrecordid>eNpVkctLAzEQh4MoVqtHr5Kjl9U8mti9CKX4goIXPcdpHt3IblKTVOx_79ZW0dMMMx-_GfgQOqPkkpKaXwW7ikFfhVgIo3voiArGKzGWcv-7Z9VY0OsBOs75jfSEkPQQDRgfScLp-Ai9TvCygWzxIy7JQ4ujw5CyDV5vBvHTG4t1Y7uYwPhYGptgucYuJuyD821JUHxYYMglRb0usYO8ydCNb00TozlBBw7abE93dYhe7m6fpw_V7On-cTqZVXrESKkccZKMiTXOCSHAaO1EDdRq4IwxYpjQlM1BcEbdSJPacV2DlHNhJDHXxvIhutnmLlfzzhptQ_9aq5bJd5DWKoJX_zfBN2oRPxSXklLC-oCLXUCK7yubi-p81rZtIdi4yooKQSXlopY9Wm1RnWLOybrfM5SojRW1taK2Vnr-_O9vv_SPBv4F6r2OZQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1551613596</pqid></control><display><type>article</type><title>A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Cohen, Kenneth J ; Gibbs, Iris C ; Fisher, Paul G ; Hayashi, Robert J ; Macy, Margaret E ; Gore, Lia</creator><creatorcontrib>Cohen, Kenneth J ; Gibbs, Iris C ; Fisher, Paul G ; Hayashi, Robert J ; Macy, Margaret E ; Gore, Lia</creatorcontrib><description>Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas.
We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable.
ATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation.
The recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/not021</identifier><identifier>PMID: 23460318</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adolescent ; Adult ; Antineoplastic Agents - therapeutic use ; Arsenicals - therapeutic use ; Astrocytoma - mortality ; Astrocytoma - pathology ; Astrocytoma - therapy ; Brain Stem Neoplasms - mortality ; Brain Stem Neoplasms - pathology ; Brain Stem Neoplasms - therapy ; Chemoradiotherapy ; Child ; Child, Preschool ; Clinical Investigations ; Dose Fractionation ; Female ; Follow-Up Studies ; Humans ; Male ; Neoplasm Grading ; Oxides - therapeutic use ; Prognosis ; Survival Rate ; Young Adult</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2013-06, Vol.15 (6), p.783-787</ispartof><rights>The Author(s) 2013. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-f0f6080edff555adccf59a1eca32220d25c12ba5321f4c09f3c9a66b5d60d7de3</citedby><cites>FETCH-LOGICAL-c420t-f0f6080edff555adccf59a1eca32220d25c12ba5321f4c09f3c9a66b5d60d7de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661102/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661102/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23460318$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cohen, Kenneth J</creatorcontrib><creatorcontrib>Gibbs, Iris C</creatorcontrib><creatorcontrib>Fisher, Paul G</creatorcontrib><creatorcontrib>Hayashi, Robert J</creatorcontrib><creatorcontrib>Macy, Margaret E</creatorcontrib><creatorcontrib>Gore, Lia</creatorcontrib><title>A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood</title><title>Neuro-oncology (Charlottesville, Va.)</title><addtitle>Neuro Oncol</addtitle><description>Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas.
We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable.
ATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation.
The recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Arsenicals - therapeutic use</subject><subject>Astrocytoma - mortality</subject><subject>Astrocytoma - pathology</subject><subject>Astrocytoma - therapy</subject><subject>Brain Stem Neoplasms - mortality</subject><subject>Brain Stem Neoplasms - pathology</subject><subject>Brain Stem Neoplasms - therapy</subject><subject>Chemoradiotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clinical Investigations</subject><subject>Dose Fractionation</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasm Grading</subject><subject>Oxides - therapeutic use</subject><subject>Prognosis</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkctLAzEQh4MoVqtHr5Kjl9U8mti9CKX4goIXPcdpHt3IblKTVOx_79ZW0dMMMx-_GfgQOqPkkpKaXwW7ikFfhVgIo3voiArGKzGWcv-7Z9VY0OsBOs75jfSEkPQQDRgfScLp-Ai9TvCygWzxIy7JQ4ujw5CyDV5vBvHTG4t1Y7uYwPhYGptgucYuJuyD821JUHxYYMglRb0usYO8ydCNb00TozlBBw7abE93dYhe7m6fpw_V7On-cTqZVXrESKkccZKMiTXOCSHAaO1EDdRq4IwxYpjQlM1BcEbdSJPacV2DlHNhJDHXxvIhutnmLlfzzhptQ_9aq5bJd5DWKoJX_zfBN2oRPxSXklLC-oCLXUCK7yubi-p81rZtIdi4yooKQSXlopY9Wm1RnWLOybrfM5SojRW1taK2Vnr-_O9vv_SPBv4F6r2OZQ</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Cohen, Kenneth J</creator><creator>Gibbs, Iris C</creator><creator>Fisher, Paul G</creator><creator>Hayashi, Robert J</creator><creator>Macy, Margaret E</creator><creator>Gore, Lia</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>20130601</creationdate><title>A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood</title><author>Cohen, Kenneth J ; Gibbs, Iris C ; Fisher, Paul G ; Hayashi, Robert J ; Macy, Margaret E ; Gore, Lia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-f0f6080edff555adccf59a1eca32220d25c12ba5321f4c09f3c9a66b5d60d7de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Arsenicals - therapeutic use</topic><topic>Astrocytoma - mortality</topic><topic>Astrocytoma - pathology</topic><topic>Astrocytoma - therapy</topic><topic>Brain Stem Neoplasms - mortality</topic><topic>Brain Stem Neoplasms - pathology</topic><topic>Brain Stem Neoplasms - therapy</topic><topic>Chemoradiotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clinical Investigations</topic><topic>Dose Fractionation</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasm Grading</topic><topic>Oxides - therapeutic use</topic><topic>Prognosis</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Kenneth J</creatorcontrib><creatorcontrib>Gibbs, Iris C</creatorcontrib><creatorcontrib>Fisher, Paul G</creatorcontrib><creatorcontrib>Hayashi, Robert J</creatorcontrib><creatorcontrib>Macy, Margaret E</creatorcontrib><creatorcontrib>Gore, Lia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Kenneth J</au><au>Gibbs, Iris C</au><au>Fisher, Paul G</au><au>Hayashi, Robert J</au><au>Macy, Margaret E</au><au>Gore, Lia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><addtitle>Neuro Oncol</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>15</volume><issue>6</issue><spage>783</spage><epage>787</epage><pages>783-787</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas.
We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable.
ATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation.
The recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>23460318</pmid><doi>10.1093/neuonc/not021</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1522-8517 |
| ispartof | Neuro-oncology (Charlottesville, Va.), 2013-06, Vol.15 (6), p.783-787 |
| issn | 1522-8517 1523-5866 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3661102 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adolescent Adult Antineoplastic Agents - therapeutic use Arsenicals - therapeutic use Astrocytoma - mortality Astrocytoma - pathology Astrocytoma - therapy Brain Stem Neoplasms - mortality Brain Stem Neoplasms - pathology Brain Stem Neoplasms - therapy Chemoradiotherapy Child Child, Preschool Clinical Investigations Dose Fractionation Female Follow-Up Studies Humans Male Neoplasm Grading Oxides - therapeutic use Prognosis Survival Rate Young Adult |
| title | A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A51%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20I%20trial%20of%20arsenic%20trioxide%20chemoradiotherapy%20for%20infiltrating%20astrocytomas%20of%20childhood&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Cohen,%20Kenneth%20J&rft.date=2013-06-01&rft.volume=15&rft.issue=6&rft.spage=783&rft.epage=787&rft.pages=783-787&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/not021&rft_dat=%3Cproquest_pubme%3E1551613596%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1551613596&rft_id=info:pmid/23460318&rfr_iscdi=true |